BioPharmSignal logoBioPharmSignal

Biotech News

Bionano Reports Fourth Quarter and Full-Year 2025 Results and Provides Revenue Outlook for 2026

BioNano Genomics (BNGO)BioNano GenomicsEarnings

Conference call today, March 23, 2026, at 4:30 PM ET SAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2025. "2025 demonstrated the momentum we built as a business,” commented

Related news

BNGOBioNano Genomics2026-03-09 20:05 EST

Bionano to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call Webcast on March 23, 2026

BNGOBioNano Genomics2026-08-10 20:05 EST

Bionano Reports Second Quarter 2026 Results and Provides a Business Update

View all latest news

BioNano Genomics

Genome Analysis Platform Bionano provides optical genome mapping systems and software for identifying structural variants and interpreting genomic data. Saphyr and OGM The Saphyr platform images ultra-high-molecular-weight DNA to detect large genomic changes that can be missed by conventional cytogenetics or short-read sequencing. VIA...

Recent company news

BNGOBioNano Genomics2026-08-24 12:00 EST

Bionano to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

BNGOBioNano Genomics2026-08-10 20:05 EST

Bionano Reports Second Quarter 2026 Results and Provides a Business Update

BNGOBioNano Genomics2026-07-27 20:05 EST

Bionano to Report Second Quarter 2026 Financial Results and Host a Conference Call Webcast on August 10, 2026

BNGOBioNano Genomics2026-06-24 12:30 EST

Bionano Announces Hiring of Chief Scientific Officer

BNGOBioNano Genomics2026-06-18 12:00 EST

Bionano Announces 67% Year-Over-Year Growth in Studies Featuring Optical Genome Mapping at ESHG 2026, Reflecting Expanding Global Adoption

Stock data

Close
1.20 USD
Market cap
14.46M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States